A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
NCT ID: NCT04586231
Last Updated: 2025-04-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
708 participants
INTERVENTIONAL
2021-02-25
2027-02-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary hypothesis is that belzutifan + lenvatinib is superior to cabozantinib in terms of progression-free survival or overall survival.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)
NCT05030506
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
NCT04489771
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
NCT05468697
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
NCT04195750
A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)
NCT04846920
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Belzutifan + Lenvatinib
Belzutifan 120 mg and lenvatinib 20 mg orally once a day
Belzutifan
Immediate-release 40 mg tablet
Lenvatinib
Capsule available in 4 mg and 10 mg dosages
Cabozantinib
Cabozantinib 60 mg orally once a day
Cabozantinib
Tablet available in 20 mg, 40 mg and 60 mg dosages
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Belzutifan
Immediate-release 40 mg tablet
Lenvatinib
Capsule available in 4 mg and 10 mg dosages
Cabozantinib
Tablet available in 20 mg, 40 mg and 60 mg dosages
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Disease progression on or after an anti-programmed cell death-1/ligand 1 (PD-1/L1) therapy as either first or second-line treatment for locally advanced/metastatic RCC or as adjuvant treatment or neoadjuvant/adjuvant with progression on or within 6 months of last dose.
* Measurable disease per RECIST 1.1 criteria as assessed by local study investigator.
* Karnofsky performance status (KPS) score of at least 70% assessed within 10 days before randomization.
* Received no more than 2 prior systemic regimens including: one anti-PD-1/L1 containing adjuvant or neoadjuvant/adjuvant regimens with progression on or within 6 months from the last dose of that regimen OR one or 2 regimens for locoregional/advanced disease
* Received only 1 prior antiPD-1/L1 therapy for adjuvant, neoadjuvant/adjuvant or locally advanced/metastatic RCC.
* A male participant is eligible to participate if he is abstinent from heterosexual intercourse or agrees to use contraception during the intervention period and for at least 7 days after the last dose of belzutifan or lenvatinib in the belzutifan+lenvatinib arm, whichever occurs last, and 23 days after the last dose of cabozantinib.
* A female participant is eligible to participate if they are not pregnant, not breastfeeding, and at least 1 of the following conditions applies: Not a woman of childbearing potential (WOCBP) or a WOCBP who agrees to follow the contraceptive guidance during the intervention period and for at least 30 days after the last dose of study intervention in the belzutifan+ lenvatinib arm, or 120 days after the last dose of study intervention in the cabozantinib arm.
* Adequately controlled blood pressure.
* Adequate organ function.
Exclusion Criteria
* Known additional malignancy that is progressing or has required active treatment within the past 3 years except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy.
* Known central nervous system (CNS) metastases and/or carcinomatous meningitis.
* Clinically significant cardiac disease within 6 months of first dose of study intervention.
* Prolongation of QTc interval to \>480 ms.
* Symptomatic pleural effusion (e.g.,cough, dyspnea, pleuritic chest pain) that is not clinically stable.
* Pre-existing ≥Grade 3 gastrointestinal or nongastrointestinal fistula.
* Moderate to severe hepatic impairment.
* History of significant bleeding within 3 months before randomization.
* History of solid organ transplantation.
* Known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study.
* Unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption (e.g., gastrectomy, partial bowel obstruction, malabsorption).
* Known hypersensitivity or allergy to the active pharmaceutical ingredients or any component of the study intervention formulations.
* Received colony-stimulating factors \[eg, granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GMCSF) or recombinant erythropoietin (EPO)\] within 28 days before randomization.
* Prior treatment with belzutifan or another hypoxia-inducible factor (HIF)-2α inhibitor.
* Prior treatment with lenvatinib.
* Prior treatment with cabozantinib.
* Currently participating in a study of an investigational agent or using an investigational device.
* Active infection requiring systemic therapy.
* History of human immunodeficiency virus (HIV) infection.
* History of hepatitis B or known active hepatitis C infection.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eisai Inc.
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ironwood Cancer & Research Centers ( Site 0077)
Chandler, Arizona, United States
Cedars Sinai Medical Center ( Site 0027)
Los Angeles, California, United States
UCLA Hematology/Oncology - Santa Monica ( Site 0048)
Los Angeles, California, United States
St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0095)
Orange, California, United States
UC Irvine Health ( Site 0029)
Orange, California, United States
Providence Saint John's Health Center ( Site 0083)
Santa Monica, California, United States
Georgetown University Medical Center ( Site 0006)
Washington D.C., District of Columbia, United States
AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlando ( Site 0003)
Orlando, Florida, United States
Orlando Health, Inc. ( Site 0035)
Orlando, Florida, United States
University Cancer & Blood Center, LLC ( Site 0057)
Athens, Georgia, United States
Emory University Hospital ( Site 0012)
Atlanta, Georgia, United States
Rush University Medical Center ( Site 0040)
Chicago, Illinois, United States
Illinois Cancer Care, PC ( Site 0008)
Peoria, Illinois, United States
Parkview Cancer Institute ( Site 0088)
Fort Wayne, Indiana, United States
Norton Cancer Institute - St. Matthews ( Site 0065)
Louisville, Kentucky, United States
Tulane University School of Medicine ( Site 0098)
New Orleans, Louisiana, United States
Lahey Hospital & Medical Center ( Site 0090)
Burlington, Massachusetts, United States
Cancer & Hematology Centers of Western Michigan ( Site 0018)
Grand Rapids, Michigan, United States
HealthPartners Cancer Research Center-HealthPartners Frauenshuh Cancer Center ( Site 0005)
Saint Louis Park, Minnesota, United States
University of Mississippi Medical Ctr ( Site 0037)
Jackson, Mississippi, United States
Cancer Partners of Nebraska ( Site 0086)
Lincoln, Nebraska, United States
Rutgers Cancer Institute of New Jersey ( Site 0078)
New Brunswick, New Jersey, United States
R.J. Zuckerberg Cancer Center-Medical Oncology ( Site 0013)
Lake Success, New York, United States
Memorial Sloan Kettering Cancer Center ( Site 0055)
New York, New York, United States
Levine Cancer Institute ( Site 0004)
Charlotte, North Carolina, United States
Duke Cancer Institute ( Site 0096)
Durham, North Carolina, United States
Lehigh Valley Hospital- Cedar Crest-Oncology Clinical Trials ( Site 0056)
Allentown, Pennsylvania, United States
University of Texas, Southwestern Medical Center ( Site 0015)
Dallas, Texas, United States
Huntsman Cancer Institute-HCI Clinical Trials Office ( Site 7001)
Salt Lake City, Utah, United States
University of Vermont Medical Center ( Site 0001)
Burlington, Vermont, United States
Blue Ridge Cancer Care - Roanoke ( Site 0043)
Roanoke, Virginia, United States
Seattle Cancer Care Alliance-Renal/Melanoma/MCC ( Site 0093)
Seattle, Washington, United States
Confluence Health | Wenatchee Valley Hospital & Clinics ( Site 0061)
Wenatchee, Washington, United States
Centro de Urología (CDU) ( Site 0803)
CABA, Buenos Aires, Argentina
Hospital Británico de Buenos Aires-Oncology ( Site 0801)
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Instituto Alexander Fleming ( Site 0800)
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Sanatorio Británico-Clinical Oncology Department ( Site 0802)
Rosario, Santa Fe Province, Argentina
Sanatorio Parque ( Site 0806)
Rosario, Santa Fe Province, Argentina
Asociación de Beneficencia Hospital Sirio Libanés ( Site 0804)
Buenos Aires, , Argentina
GenesisCare North Shore ( Site 4011)
St Leonards, New South Wales, Australia
Lyell McEwin Hospital ( Site 4004)
Elizabeth Vale, South Australia, Australia
Peninsula Health Frankston Hospital ( Site 4001)
Frankston, Victoria, Australia
Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 4010)
Melbourne, Victoria, Australia
Medizinische Universitätsklinik Graz ( Site 1051)
Graz, Styria, Austria
Ordensklinikum Linz GmbH Elisabethinen-Urologie ( Site 1001)
Linz, Upper Austria, Austria
Klinik Ottakring-1.Medizinische Abteilung - Zentrum für Onkologie und Hämatologie ( Site 1031)
Vienna, Vienna, Austria
Krankenhaus der Barmherzigen Brüder Wien ( Site 1041)
Vienna, , Austria
Medizinische Universität Wien ( Site 1021)
Vienna, , Austria
Institut Jules Bordet ( Site 1103)
Anderlecht, Bruxelles-Capitale, Region de, Belgium
Cliniques Universitaires Saint Luc - Bruxelles ( Site 1105)
Brussels, Bruxelles-Capitale, Region de, Belgium
Grand Hopital de Charleroi ( Site 1104)
Charleroi, Hainaut, Belgium
UZ Gent ( Site 1100)
Ghent, Oost-Vlaanderen, Belgium
UZ Leuven ( Site 1101)
Leuven, Vlaams-Brabant, Belgium
CHU de Liege ( Site 1102)
Liège, , Belgium
Liga Norte Riograndense Contra o Cancer ( Site 0313)
Natal, Rio Grande do Norte, Brazil
Centro Gaucho Integrado de Oncologia ( Site 0304)
Porto Alegre, Rio Grande do Sul, Brazil
BP - A Beneficencia Portuguesa de São Paulo-Medical Oncology ( Site 0311)
São Paulo, , Brazil
Hospital Paulistano - Amil Clinical Research ( Site 0308)
São Paulo, , Brazil
Tom Baker Cancer Centre ( Site 0109)
Calgary, Alberta, Canada
Cross Cancer Institute ( Site 0111)
Edmonton, Alberta, Canada
BC Cancer Vancouver-Clinical Trials Unit ( Site 0110)
Vancouver, British Columbia, Canada
The Moncton Hospital ( Site 0101)
Moncton, New Brunswick, Canada
Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0114)
Hamilton, Ontario, Canada
Kingston Health Sciences Centre ( Site 0105)
Kingston, Ontario, Canada
The Ottawa Hospital - General Campus-The Ottawa Hospital Cancer Centre ( Site 0116)
Ottawa, Ontario, Canada
Sunnybrook Health Sciences - Odette Cancer Centre ( Site 0113)
Toronto, Ontario, Canada
CISSS de la Monteregie-Centre ( Site 0103)
Greenfield Park, Quebec, Canada
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0
Québec, Quebec, Canada
CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0102)
Sherbrooke, Quebec, Canada
Bradfordhill-Clinical Area ( Site 0400)
Santiago, Region M. de Santiago, Chile
James Lind Centro de Investigación del Cáncer ( Site 0402)
Temuco, Región de la Araucanía, Chile
Fundación Colombiana de Cancerología Clínica Vida ( Site 0505)
Medellín, Antioquia, Colombia
Sociedad De Oncologia Y Hematologia Del Cesar-Oncology ( Site 0508)
Valledupar, Cesar Department, Colombia
Instituto Nacional de Cancerología-Clinical Oncology ( Site 0500)
Bogotá, Cundinamarca, Colombia
Fundación Cardiovascular de Colombia ( Site 0501)
Piedecuesta, Santander Department, Colombia
Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 2203)
Brno, Brno-mesto, Czechia
Nemocnice České Budějovice-Onkologicke oddeleni ( Site 2204)
České Budějovice, Jihočeský kraj, Czechia
Fakultni Thomayerova nemocnice-Onkologicka klinika 1. LF UK ( Site 2200)
Prague, Praha 4, Czechia
Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 2205)
Prague, Praha 5, Czechia
Fakultni nemocnice Hradec Kralove-Klinika onkologie a radioterapie ( Site 2201)
Hradec Králové, , Czechia
Tampereen yliopistollinen sairaala ( Site 1801)
Tampere, Pirkanmaa, Finland
TYKS ( Site 1802)
Turku, Southwest Finland, Finland
HYKS ( Site 1800)
Helsinki, Uusimaa, Finland
Institut Jean Godinot ( Site 1216)
Reims, Ain, France
Centre Antoine Lacassagne ( Site 1217)
Nice, Alpes-Maritimes, France
Institut de cancérologie Strasbourg Europe (ICANS) ( Site 1218)
Strasbourg, Alsace, France
CHU de Bordeaux- Hopital Saint Andre ( Site 1209)
Bordeaux, Gironde, France
Institut Claudius Regaud ( Site 1215)
Toulouse, Haute-Garonne, France
Clinique Francois Chenieux ( Site 1210)
Limoges, Haute-Vienne, France
Institut de Cancerologie de l Ouest Centre Rene Gauducheau ( Site 1201)
Saint-Herblain, Loire-Atlantique, France
Institut de Cancerologie de l Ouest Site Paul Papin ( Site 1200)
Angers, Maine-et-Loire, France
Hopital Tenon ( Site 1213)
Paris, , France
Klinik fuer Urologie ( Site 1303)
Freiburg im Breisgau, Baden-Wurttemberg, Germany
NCT-Department of Medical Oncology ( Site 1320)
Heidelberg, Baden-Wurttemberg, Germany
Klinikum Nuernberg Nord ( Site 1300)
Nuremberg, Bavaria, Germany
Universitaetsklinikum Frankfurt ( Site 1301)
Frankfurt am Main, Hesse, Germany
Universitaetsklinikum Aachen AOER ( Site 1317)
Aachen, North Rhine-Westphalia, Germany
Universitaetsklinikum des Saarlandes ( Site 1305)
Homburg/ Saar, Saarland, Germany
Krankenhaus Martha Maria Halle-Doelau ( Site 1314)
Halle, Saxony-Anhalt, Germany
Helios Klinikum Erfurt GmbH ( Site 1315)
Erfurt, Thuringia, Germany
Charite Universitaetsmedizin Berlin ( Site 1321)
Berlin, , Germany
HELIOS Klinikum Berlin-Buch ( Site 1311)
Berlin, , Germany
UNIVERSITY HOSPITAL OF PATRAS-DIVISION OF ONCOLOGY ( Site 3302)
Pátrai, Achaia, Greece
Alexandra General Hospital of Athens-ONCOLOGY DEPT. ( Site 3304)
Athens, Attica, Greece
Athens Medical Center ( Site 3303)
Athens, Attica, Greece
ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 3301)
Chaïdári, Attica, Greece
European Interbalkan Medical Center-Oncology Department ( Site 3300)
Thessaloniki, , Greece
Mater Misericordiae University Hospital ( Site 3201)
Dublin, Dublin, Ireland
Tallaght University Hospital ( Site 3200)
Dublin, , Ireland
Mater Private Hospital - Dublin ( Site 3202)
Dublin, , Ireland
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 1407)
Meldola, Forli-Cesena, Italy
Istituto Clinico Humanitas Research Hospital ( Site 1406)
Rozzano, Milano, Italy
Ospedale San Luigi Gonzaga ( Site 1405)
Orbassano, Torino, Italy
Medical Oncology Ospedale San Donato ( Site 1404)
Arezzo, , Italy
Azienda Ospedaliera Policlinico di Bari ( Site 1402)
Bari, , Italy
IRCCS Ospedale San Raffaele ( Site 1409)
Milan, , Italy
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 1400)
Milan, , Italy
Istituti Clinici Scientifici Maugeri Spa ( Site 1403)
Pavia, , Italy
Fondazione Policlinico Universitario Agostino Gemelli-Medical Oncology ( Site 1410)
Roma, , Italy
Azienda Ospedaliera S. Maria di Terni ( Site 1401)
Terni, , Italy
Ospedale Maggiore Borgo Trento ( Site 1408)
Verona, , Italy
Fujita Health University ( Site 5003)
Toyoake, Aichi-ken, Japan
National Cancer Center Hospital East ( Site 5000)
Kashiwa, Chiba, Japan
Toho University Sakura Medical Center ( Site 5014)
Sakura, Chiba, Japan
Sapporo Medical University Hospital ( Site 5008)
Sapporo, Hokkaido, Japan
Kobe City Medical Center General Hospital ( Site 5017)
Kobe, Hyōgo, Japan
Yokohama City University Hospital ( Site 5007)
Yokohama, Kanagawa, Japan
Nara Medical University Hospital ( Site 5002)
Kashihara, Nara, Japan
Kindai University Hospital- Osakasayama Campus-Urology ( Site 5010)
Sayama, Osaka, Japan
Osaka University Hospital ( Site 5012)
Suita, Osaka, Japan
Hamamatsu University School of Medicine University Hospital ( Site 5004)
Hamamatsu, Shizuoka, Japan
Tokyo Medical and Dental University Hospital ( Site 5009)
Bunkyo-ku, Tokyo, Japan
Toranomon Hospital ( Site 5001)
Minato-ku, Tokyo, Japan
Kyushu University Hospital ( Site 5005)
Fukuoka, , Japan
Niigata University Medical & Dental Hospital ( Site 5013)
Niigata, , Japan
Osaka International Cancer Institute ( Site 5016)
Osaka, , Japan
Nippon Medical School Hospital ( Site 5006)
Tokyo, , Japan
Tokyo Women's Medical University Adachi Medical Center ( Site 5015)
Tokyo, , Japan
Keio university hospital ( Site 5011)
Tokyo, , Japan
Zuyderland Medical Centre-Trialbureau Interne Geneeskunde ( Site 1904)
Sittard-Geleen, Limburg, Netherlands
Amphia Hospital Location Molengracht ( Site 1912)
Breda, North Brabant, Netherlands
Antoni van Leeuwenhoek Ziekenhuis ( Site 1901)
Amsterdam, North Holland, Netherlands
Medisch Centrum Leeuwarden ( Site 1905)
Leeuwarden, Provincie Friesland, Netherlands
Erasmus MC ( Site 1913)
Rotterdam, South Holland, Netherlands
Franciscus Gasthuis & Vlietland, Locatie Vlietland ( Site 1909)
Schiedam, South Holland, Netherlands
Haga Ziekenhuis locatie Leyweg-Oncology ( Site 1917)
The Hague, South Holland, Netherlands
Universitair Medisch Centrum Utrecht ( Site 1910)
Utrecht, , Netherlands
Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 2401)
Poznan, Greater Poland Voivodeship, Poland
Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 2402)
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - O-Klinika Onkologii Klinicznej ( Site 240
Krakow, Lesser Poland Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 2400)
Warsaw, Masovian Voivodeship, Poland
Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 2500)
Cluj-Napoca, Cluj, Romania
Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 2501)
Cluj-Napoca, Cluj, Romania
Centrul de Oncologie "Sfântul Nectarie" ( Site 2502)
Craiova, Dolj, Romania
Ivanovo Regional Oncology Dispensary ( Site 2616)
Ivanovo, Ivanovo Oblast, Russia
FSBI United Hospital with Polyclinic ( Site 2613)
Moscow, Moscow, Russia
SHI of Moscow City Oncology Clinical Hospital - 62 ( Site 2614)
Moscow, Moscow, Russia
MEDSI Clinical Hospital on Pyatnitsky Highway-Departmentof Antitumor Drug therapy ( Site 2618)
Krasnogorsk, Moscow Oblast, Russia
Hadassah Medical-Oncology department ( Site 2609)
Moscow, Moscow Oblast, Russia
Volgograd Regional Uronephrological Center ( Site 2615)
Volzhsky, Volgograd Oblast, Russia
Yaroslavl Regional Cancer Hospital-Oncology ( Site 2619)
Yaroslavl, Yaroslavl Oblast, Russia
Chonnam National University Hwasun Hospital-Oncology ( Site 4203)
Hwasun, Jeonranamdo, South Korea
Asan Medical Center ( Site 4200)
Seoul, , South Korea
Samsung Medical Center ( Site 4201)
Seoul, , South Korea
Complejo Hospitalario Universitario A Coruna ( Site 1502)
A Coruña, La Coruna, Spain
Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1508)
Madrid, Madrid, Comunidad de, Spain
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1507)
Barcelona, , Spain
Hospital Clinic i Provincial ( Site 1500)
Barcelona, , Spain
Hospital Santa Creu i Sant Pau ( Site 1501)
Barcelona, , Spain
Hospital General Universitario Gregorio Maranon ( Site 1505)
Madrid, , Spain
Hospital Clinico San Carlos ( Site 1504)
Madrid, , Spain
Hospital Virgen del Rocio ( Site 1503)
Seville, , Spain
Hopitaux Universitaires de Geneve HUG ( Site 1602)
Geneva, Canton of Geneva, Switzerland
Universitaetsspital Zuerich ( Site 1601)
Zurich, Canton of Zurich, Switzerland
Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 1604)
Bellinzona, Canton Ticino, Switzerland
Kantonsspital Graubuenden ( Site 1600)
Chur, Kanton Graubünden, Switzerland
Aberdeen Royal Infirmary-Department of Oncology ( Site 3105)
Aberdeen, Aberdeen City, United Kingdom
Royal United Hospital Bath England ( Site 3108)
Bath, Bath And North East Somerset, United Kingdom
Nottingham University Hospitals NHS Trust. City Hospital Campus ( Site 3106)
Nottingham, England, United Kingdom
Southend University Hospital ( Site 3112)
Southend, Essex, United Kingdom
Imperial Healthcare NHS Trust Charing Cross Hospital ( Site 3107)
London, London, City of, United Kingdom
Mount Vernon Cancer Centre ( Site 3101)
Northwood, London, City of, United Kingdom
Musgrove Park Hospital ( Site 3103)
Taunton, Somerset, United Kingdom
Singleton Hospital ( Site 3111)
Swansea, Wales, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Motzer RJ, Schmidinger M, Eto M, Suarez C, Figlin R, Liu Y, Perini R, Zhang Y, Heng DY. LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy. Future Oncol. 2023 Jan;19(2):113-121. doi: 10.2217/fon-2022-0802. Epub 2023 Feb 8.
Related Links
Access external resources that provide additional context or updates about the study.
Merck Clinical Trials Information
Plain Language Summary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK-6482-011
Identifier Type: OTHER
Identifier Source: secondary_id
jRCT2031210311
Identifier Type: OTHER
Identifier Source: secondary_id
2024-510620-39
Identifier Type: REGISTRY
Identifier Source: secondary_id
U1111-1302-2815
Identifier Type: REGISTRY
Identifier Source: secondary_id
2020-002075-35
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
6482-011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.